Nucleix Ltd.

Nucleix Ltd. develops, manufactures, and markets non-invasive cancer tests using its EpiCheck technology. Its Bladder EpiCheck test is CE-marked and available in Europe for specified bladder and upper urinary tract cancer uses, and has FDA 510(k) clearance in the United States for monitoring recurrence of non-muscle-invasive bladder cancer. Lung EpiCheck, a blood test in development, is intended to detect early-stage lung cancer in high-risk individuals.

Website

https://www.nucleix.com

Phone

US: +1-858-283-3398; Israel: +972-8-9161616